Model to predict which biologic works best for inflammatory bowel disease patients
Official title: Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
Run by Peking University First Hospital · NCT07181525 · Data updated 2026-11-12
This project will try to build a model that predicts which IBD patients are likely to respond to different biologic medicines using their clinical and lab data.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Status | Recruiting |
| Started | August 15, 2025 |
| Main results expected | July 1, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | September 18, 2025 |
| Trial ID | NCT07181525 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are IBD patients treated at Peking University First Hospital who are in an active disease phase, receive biologic therapy, and have baseline and follow-up clinical and biomarker data available.
✕Probably not a fit
Patients who have never received biologics, are in sustained remission, have other autoimmune diseases requiring biologics, or have severe complications such as malignancy or gastrointestinal perforation are unlikely to benefit from this project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will collect clinical characteristics, biomarker results, treatment details, and outcome data from a cohort of IBD patients treated at Peking University First Hospital. The focus is on patients receiving anti-cytokine or anti-integrin biologics during active disease. The assembled dataset will be analyzed with correlation analysis, multiple regression, and machine-learning methods to train and test predictive models of treatment response. The goal is to validate a tool that can help clinicians choose the most appropriate biologic for individual patients.
Why it matters
Potential benefit: If successful, the model could help doctors choose the biologic most likely to work for each patient, reducing ineffective treatment, side effects, and cost.
How similar studies have gone: Previous studies using biomarkers and machine-learning to predict biologic response in IBD have shown some promising but inconsistent results and generally lack broad external validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are clinically diagnosed with IBD in our hospital * Disease activity is in the active stage * Receiving biologics after diagnosis * Have relevant data on clinical evaluation results after receiving biologics treatment Exclusion Criteria: * IBD patients who have not been treated with biologics after diagnosis * Patients diagnosed with IBD but also with other autoimmune diseases that require biologics to be treated * Patients with hematological diseases and other systemic chronic inflammatory diseases involving the intestine Patients with serious complications including malignant tumors and gastrointestinal perforation.
Where it's running
-
Peking University First Hospital
Beijing, China Recruiting
Study contacts
- Study coordinator: Raphael Hong
- Email: doctoraphael@126.com
- Phone: +86 (010)83575675
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Impact of sucralose on gut health in Crohn's disease
This study tests whether the non-nutritive sweetener sucralose changes gut bacteria in adults with Crohn's disease compared to healthy controls.
-
Postoperative biologic therapy in Crohn's disease: which agent works best to prevent recurrence after surgery?
This study looks back at adults with Crohn's disease to see if different biologic medicines given after ileocecal or other bowel surgery help prevent endoscopic recurrence within a year.
-
Fecal microbiome signature of multi-strain probiotic supplementation in children and adolescents with inflammatory bowel disease
We will test whether giving a multi-strain probiotic changes the gut microbiome in kids and teens with inflammatory bowel disease.
-
Guselkumab for adults with Crohn's disease after ustekinumab failure
This study will try guselkumab for adults with moderate to severe Crohn's disease who did not respond to or could not tolerate ustekinumab to see if they reach remission after 52 weeks.
-
Guselkumab plus a JAK inhibitor for difficult-to-treat inflammatory bowel disease
This project will try guselkumab together with a JAK inhibitor in people aged 14–80 whose moderate-to-severe inflammatory bowel disease has not responded to multiple other treatments.
-
68Ga-FAPI-46 PET/CT to detect small bowel fibrostenosis in Crohn's disease
This study will try whether a PET tracer called 68Ga‑FAPI‑46 can find early or developing fibrosis and strictures in the small bowel of adults with Crohn's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.